tradingkey.logo

Vor Biopharma Inc

VOR

2.170USD

0.000
Cierre 08/22, 16:00ETCotizaciones retrasadas 15 min
272.65MCap. mercado
PérdidaP/E TTM

Vor Biopharma Inc

2.170

0.000
Más Datos de Vor Biopharma Inc Compañía
Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.
Información de la empresa
Símbolo de cotizaciónVOR
Nombre de la empresaVor Biopharma Inc
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoDr. Jean-Paul Kress, M.D.
Número de empleados159
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
Dirección100 Cambridgepark Drive
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02140
Teléfono16176556580
Sitio Webhttps://www.vorbio.com/
Símbolo de cotizaciónVOR
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoDr. Jean-Paul Kress, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Independent Director
Independent Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Dallan Murray
Mr. Dallan Murray
Chief Commercial Officer
Chief Commercial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Sandesh (Sandy) Mahatme
Mr. Sandesh (Sandy) Mahatme
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
13.88M
--
Dr. Qing Zuraw
Dr. Qing Zuraw
Chief Development Officer
Chief Development Officer
937.08K
--
Mr. Erez Kalir
Mr. Erez Kalir
Independent Director
Independent Director
--
--
Mr. David Charles Lubner, CPA
Mr. David Charles Lubner, CPA
Independent Director
Independent Director
--
--
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
31.30%
Reprogrammed Interchange LLC
30.77%
Mahatme (Sandesh)
10.96%
5AM Ventures
3.49%
Fidelity Management & Research Company LLC
1.59%
Otro
21.90%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
31.30%
Reprogrammed Interchange LLC
30.77%
Mahatme (Sandesh)
10.96%
5AM Ventures
3.49%
Fidelity Management & Research Company LLC
1.59%
Otro
21.90%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
35.67%
Corporation
30.77%
Individual Investor
12.08%
Investment Advisor
5.49%
Hedge Fund
0.98%
Research Firm
0.71%
Investment Advisor/Hedge Fund
0.67%
Bank and Trust
0.14%
Otro
13.51%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
165
100.29M
80.27%
+23.22M
2025Q1
174
100.82M
80.73%
+21.38M
2024Q4
172
101.57M
81.78%
+39.14M
2024Q3
175
49.60M
72.03%
-12.93M
2024Q2
174
56.25M
82.04%
-8.25M
2024Q1
168
60.63M
88.57%
-4.75M
2023Q4
163
60.90M
89.54%
-3.77M
2023Q3
164
61.10M
90.20%
-4.10M
2023Q2
166
61.68M
92.10%
-1.24M
2023Q1
168
61.85M
93.27%
-1.28M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
39.65M
31.73%
--
--
Jun 25, 2025
Reprogrammed Interchange LLC
38.97M
31.19%
+38.97M
--
Dec 30, 2024
5AM Ventures
6.36M
5.09%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
6.34M
5.07%
+5.39K
+0.09%
Mar 31, 2025
The Vanguard Group, Inc.
1.94M
1.55%
-2.60K
-0.13%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
1.07M
0.86%
--
--
Mar 31, 2025
Jane Street Capital, L.L.C.
194.76K
0.16%
+194.76K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Proshares Ultra Russell 2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI